Prima sets sights on $10m capital raising
07 October, 2004 by Renate KrelleMelbourne's Prima Biomed (ASX:PRR) is aiming to raise between $5 and $10 million over the next two weeks to fund its research programs - particularly its Panvax vaccine technology.
Cross-linked beta-amyloid implicated in Alzheimers
06 October, 2004 by Melissa TrudingerCross-linked oligomers of beta-amyloid (AB) may be the primary neurotoxic agent in Alzheimer's disease according to Rob Moir, an expatriate Australian researcher in Rudolph Tanzi's Genetics and Aging Research Unit at Massachusetts General Hospital and Harvard University.
Acrux completes Phase I trial of testosterone lotion
06 October, 2004 by Melissa TrudingerAcrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
Psiron to raise $10.5m to buy licence, boost R&D
06 October, 2004 by Renate KrelleWith plans for its anti-cancer virus therapy mapped out, Psiron (ASX:PSX) today lodged a prospectus for a non-renounceable rights issue to raise approximately $10.5 million at $0.20 a share.
Pfizer says no safety concerns in Celebrex studies
05 October, 2004 by Staff WritersThree long-term studies conducted by Pfizer seeking additional uses for its popular arthritis drug Celebrex have turned up no cardiovascular safety concerns, according to the company
Peplin trading halted
05 October, 2004 by Melissa TrudingerBrisbane based Peplin Biotech (ASX:PEP) has called a halt to trading shares on the ASX for at least a week, telling shareholders to expect a major announcement.
Solbec progresses psoriasis trial
05 October, 2004 by Melissa TrudingerSolbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
Boston's Athena Diagnostics to market Bionomics epilepsy test
27 September, 2004 by Graeme O'NeillSouth Australian biopharma Bionomics(ASX:BNO) announced today it has licensed Boston company Athena Diagnostics to market its test for severe myoclonic epilepsy of infancy (SMEI) to neurologists in North America and Japan.
Avexa lists on ASX
23 September, 2004 by Melissa TrudingerAmrad (AML) spin-off Avexa (ASX: AVX) listed on the ASX this morning with trading hovering around AUD$0.265.
Leukemia expert joins Chemgenex
22 September, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (ASX: CXS) announced today that leukemia expert Hagop Kantarjian, chairman of the leukemia department at the MD Anderson Cancer Center in Texas, has joined its scientific advisory board.
Neuroblastoma may be due to gene interference
22 September, 2004 by Melissa TrudingerResearchers at Sydney's Children's Cancer Institute of Australia (CCIA) have identified a possible mechanism for the formation of tumours from embryonic cells.
AIMS teams with European biopharma on cancer project
15 September, 2004 by Melissa TrudingerThe Australian Institute of Marine Science (AIMS) has entered into a collaborative agreement with Austrian-German drug development company Faustus to develop new anti-cancer leads from natural sources.
AustCancer acquires licence to pancreatic cancer drug
10 September, 2004 by Renate KrelleAustralian Cancer Technology (ASX:ACU) has acquired the North American licence for a developmental pancreatic cancer drug from German company RESprotect.
NZ's billion-dollar man aims to mend diabetes' broken hearts
10 September, 2004 by Graeme O'NeillProf Garth Cooper's ambition to build his second -- and new Zealand's first -- billion-dollar biotech company appears to be on track, with his Auckland-based biopharma company Protemix announcing remarkable results from a Phase IIa clinical trial of an oral drug that reverse heart disease in type 2 diabetics.
Select Vaccines partner ships hep E kits to hotspot
08 September, 2004 by Melissa TrudingerSelect Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
